Exact Sciences saw a rise in stock value after FDA approval of its Cologuard Plus colon cancer test. The test is highly sensitive and specific, with potential to detect precancerous lesions. Analysts expect positive outcomes for the company due to Medicare reimbursement opportunities and potential guideline updates.